OTC · Healthcare

SANGAMO THERAPEUTICS, INC (SGMOQ)

As-reported financials and recent SEC filings for SANGAMO THERAPEUTICS, INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$39.6M

Net income

$-122.9M

Net margin

—

Diluted EPS

$-0.44

ROE

861.6%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$39.6M	$57.8M	$176.2M	$111.3M	$110.7M
Gross profit	—	—	—	—	—
Operating income	$-121.2M	$-104.0M	$-274.0M	$-201.3M	$-183.3M
Net income	$-122.9M	$-97.9M	$-257.8M	$-192.3M	$-178.3M
Diluted EPS	$-0.44	$-0.49	$-1.48	$-1.25	$-1.23

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-07-01

8-K/A2026-06-23

8-K2026-06-23

42026-05-27

42026-05-27

42026-05-27

42026-05-27

42026-05-27

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on SGMOQ

Search SANGAMO THERAPEUTICS, INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.